Candidate Genes for the Diagnosis and Treatment of Alzheimer's Disease in People with Down Syndrome: Innovative Perspectives from Horizon Scanning

From a Horizon Scanning perspective, the identified genes have significant therapeutic potential for AD in DS. DYRK1A inhibitors have shown promise in preclinical studies by reducing cognitive decline and slowing disease progression. Ongoing clinical trials with non-competitive inhibitors of DYRK1A further support its relevance. Additionally, SYNJ1, SOD1, and RCAN1 are promising inflammatory markers for early AD diagnosis. Research on DYRK1A inhibitors and gene-specific therapies could drive the development of innovative diagnostic and therapeutic strategies for AD in DS and the broader population.